
Hungarian chamomile, wild chamomile, Chamomilla recutita
Chamomile, an aromatic annual herb, has a long history of use in traditional medicine to treat muscle spasms, menstrual disorders, insomnia, ulcers, wounds, stomach disorders, rheumatic pain, hay fever, and hemorrhoids. It is widely used in teas for its relaxing and calming effects.
In vitro and animal studies indicate that chamomile extracts have anti-inflammatory (11), antihyperglycemic (12), antigenotoxic (13), and anticancer (14). Apigenin, a flavone present in chamomile, has strong chemopreventive effects (15). Bisabololoxide A, another constituent of chamomile, was shown to reduce the dose of 5-fluorouracil when used together against leukemic cells (19).
Preliminary data suggest modest benefits of chamomile in improving chronic insomnia (20). Chamomile extract showed a mild to moderate effect in patients with generalized anxiety disorder (16) and may also have antidepressant effects (30). In another controlled trial, application of a chamomile compress was shown to be effective, and superior to hydrocortisone ointment, in facilitating healing of peristomal skin lesions in patients following colostomy (21).
Chamomile mouthwash reduced 5-fluorouracil-induced mucositis in hamsters (17), but data from human studies are conflicting (8) (9). More research is warranted.
The anti-inflammatory activity of chamomile involves the release of LPS-induced prostaglandin E(2) in RAW 264.7 macrophages via inhibition of COX-2 enzyme activity (11). Methanol extracts of chamomile exert anti-allergic effects by inhibiting histamine release from mast cells (23). They also showed neuroprotective activity by decreasing lipid peroxidation (LPO) and increasing superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), and total thiol levels (24). In another study, a chamomile extract was shown to afford gastroprotection against ethanol-induced ulceration by increasing glutathione levels (25). Apigenin, a flavone component of chamomile, interacts with GABA (A) (gamma-aminobutyric acid)-benzodiazepine receptors in vitro and inhibits locomotor behavior in rats (5).
People allergic to ragweed or members of the Compositae family, such as chrysanthemums, should avoid this product.
Hypersensitivity reactions including asthma, contact dermatitis, and anaphylaxis have been reported following exposure to chamomile (26) (27).
Case reports
Premature constriction of fetal ductus arteriosus has been reported following consumption of camomile tea by the mother during pregnancy (31).
A 38-year-old Caucasian man developed an episode of severe anaphylaxis with generalized urticaria, angioedema and severe dyspnea one hour after consuming chamomile tea. The symptoms improved following treatment with an intravenous antihistamine (18).
A 70-year-old woman was hospitalized with multiple internal hemorrhages following concurrent use of chamomile products and warfarin. Her symptoms resolved after treatment with intravenous heparin (28).
Anticoagulants / Antiplatelets: Chamomile may increase anticoagulant effects and inhibit platelet activity due to its coumarin content (28).
Sedatives: Chamomile may increase their effects (4).
Cytochrome P450 substrates: Chamomile inhibits CYP1A2, CYP2C9, CYP2D6 and CYP3A4 and can affect the intracellular concentration of drugs metabolized by these enzymes (29).
Amsterdam JD, Li Y, Soeller I, et al. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol. 2009 Aug;29(4):378-82.
This randomized, double-blind, placebo-controlled efficacy and tolerability trial involved 57 patients with mild to moderate generalized anxiety disorder (GAD). Patients received chamomile extract or placebo. Those in the chamomile group were given one 220 mg chamomile capsule daily/week 1; 2 capsules daily/week 2. Patients with a 50% reduction or less in total HAM-A (Hamilton Anxiety Rating) score versus baseline were increased to 3 capsules daily during week 3, and then, to 4 capsules daily during week 4 of therapy. Patients who continued to have a 50% reduction or less in baseline HAM-A score were increased to 5 capsules daily during study weeks 5 through 8 of therapy. Primary outcome was difference in change over time in total HAM-A scores. Secondary outcomes included change in the Beck Anxiety Inventory, Psychological Well Being, and Clinical Global Impression and Severity scores and the proportion of patients with 50% reduction or more in baseline HAM-A score.
A significantly greater reduction in the mean total HAM-A score was observed in the chamomile group compared to the placebo group (P = 0.047), along with a positive change in all secondary outcomes. One patient in each treatment group discontinued treatment due to adverse events, but the number of patients who experienced adverse events was not significantly different between groups (P = 0.417). Researcher concluded that chamomile may have modest benefits for those with mild to moderate GAD.
Larger studies are needed to confirm these effects.
Bottom Line: Chamomile may benefit those with anxiety disorder and insomnia. It has not been shown to treat or prevent cancer.
Several studies have used chamomile extracts in animals to test their effects. They show that substances in chamomile can kill bacteria, reduce inflammation, calm muscle spasms, inhibit the growth of polio and herpes viruses and cancer cells, and prevent the growth of ulcers. Several chemicals found in chamomile leaves are known to inhibit substances in the body that cause an inflammatory response. Apigenin, a compound isolated from chamomile, binds to brain cells in the same areas as well-known depressant drugs, which could explain chamomile's sedative effects. Small clinical trials show that chamomile may have a modest effect on generalized anxiety disorder, insomnia, and in healing skin lesions after colostomy (a surgical procedure that brings one end of the large intestine out through the abdominal wall).
Generalized Anxiety Disorder (GAD):
Fifty-seven patients with GAD were given chamomile extract or placebo. Those in the chamomile group received one 220 mg chamomile capsule daily/week 1; 2 capsules daily/week 2. Patients with a 50% reduction or less in total HAM-A (Hamilton Anxiety Rating) score were increased to 3 capsules daily during week 3, and then, to 4 capsules daily during week 4 of therapy. Patients who continued to have a 50% reduction or less in HAM-A score were increased to 5 capsules daily during study weeks 5 through 8 of therapy.
Researchers observed a significant reduction in the anxiety scores between the two groups. Chamomile may have modest benefits for those with mild to moderate GAD.